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Abstract
Background: Military operation personnel often suffer from sleep difficulty because of their work requirements. In
this study, we investigated the efficacy of zaleplon at two doses to induce afternoon-sleep under noise interference
and its effects on psychomotor performance and vestibular function; we subsequently established the optimal
dosage regimen for military operation personnel.
Methods: Twenty-two healthy young male volunteers were recruited for the study. Eight subjects took 10 mg
or 15 mg of zaleplon and placebo alternately and then were exposed to noise. Changes in polysomnography
(PSG) indices, including sleep latency (SL), sleep efficiency (SE) and sleep structure, were recorded after drug
administration. After awakening, the volunteers’ subjective judgments of sleep quality and sleepiness were measured.
Eight volunteers underwent 3 psychomotor performance tests at a one-week interval, and the psychomotor
performance tests were conducted before and after taking zaleplon and placebo. Six volunteers participated
in the vestibular function test session, and parameters, including optokinetic nystagmus (OKN), vestibular ocular reflex
(VOR), visual-vestibular ocular reflex (VVOR) and vestibular ocular reflex fixation suppression (VOR-Fix), were
detected by the same experimental design as described above. The data of sleep observations were subjected
to one-way variance analysis.
Results: Compared with the placebo group, SL was shortened significantly, and the scores of subjective sleep
quality and sleep depth were clearly increased in the zaleplon 10 mg group (P < 0.05). Moreover, the SE and the
percent of REM (rapid eye movement) sleep were increased remarkably in the zaleplon 15 mg group (P < 0.01).
Furthermore, the SE, percent of REM sleep and scores of subjective sleep depth in the zaleplon 15 mg group
were significantly higher than in the zaleplon 10 mg group (P < 0.05). The psychomotor performance did not
change significantly after ingestion of 10 mg or 15 mg of zaleplon, whereas the OKN and VOR gains were lower
in the two dose groups of zaleplon (P < 0.05) and restored to normal 3 h after drug ingestion.
Conclusion: Zaleplon is an ideal hypnotic for military personnel, and its hypnotic efficiency is dose-related
under noise interference; a 15 mg dose of zaleplon could provide significantly better sleep than a 10 mg dose
of zaleplon.
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Background
In military operations, it is common to change work
schedules and work places [1]. For example, during the
Persian Gulf War, many military units underwent short
notice transmeridian deployment with immediate com-
mencement of 24 h operations upon arrival. Some of
these individuals likely suffered from circadian desyn-
chronosis, which blunted their effectiveness [2]. There-
fore, the United Sates Air Force approved the limited
use of one short acting hypnotic medication to relieve
the sleep disorders of the aircrew on the battlefield and
one stimulant medication to enhance the alertness of
these individuals [3].
Zaleplon is a pyrazolopyrimidine compound that
selectively binds to the γ-aminobutyric acid (GABA) A
receptor complex. Zaleplon is rapidly absorbed with
peak plasma concentrations at approximately 1 h and is
rapidly eliminated with a plasma elimination half-life of
approximately 1 h [4, 5]. Zaleplon is commonly adminis-
tered at 10 mg oral doses, although various experiments
have shown some differences in the sleep-inducing
effects of zaleplon. Whitmore et al. [6] found that com-
pared with placebo, zaleplon at a 10 mg oral dose could
increase slow-wave sleep and the total sleep time in a
normal sleep environment. Stone et al. [7] investigated
the efficacy of zaleplon in promoting sleep in healthy
volunteers with noise-induced sleep maintenance insom-
nia. The results showed that zaleplon at doses of 10 mg
and 20 mg reduced the latency to persistent sleep, and
the 20 mg dose reduced N1 of non-rapid eye movement
(NREM) sleep compared with placebo. However, Simons
et al. [8] observed the usefulness of temazepam (20 mg)
and zaleplon (10 mg) to improve 4.5 h of sleep in the
afternoon and showed that the use of zaleplon at the
dose of 10 mg had no significant advantage over placebo.
Therefore, this study was conducted to assess the useful-
ness of zaleplon at two dose levels (10 mg and 15 mg) to
improve 4 h of sleep in the afternoon under strong noise
interference, to compare the effects of zaleplon on
psychomotor performance and vestibular function 1–8 h
after drug administration and to establish the optimal
dosage regimen for military operation personnel.
Methods
Subjects
Twenty-two healthy male volunteers (mean age, 22.0 years;
range, 19–33 years) participated in the study. The subjects
had no history of insomnia or smoking and were drug free
for 3 months before the study. The medical ethics com-
mittee of the Institute of Aviation Medicine, Air Force,
People’s Liberation Army, granted approval for the study.
Informed consent was obtained from all subjects after a
full explanation of the nature of the study. The subjects
were paid for their participation.
Assessment methods
A polysomnography (PSG) device (P&G9600, Beijing
Xinxing Biomedical Electronic Engineering Center,
Beijing, China) was used to record the objective sleep
quality [9]. The following parameters of sleep process
and sleep structure were calculated automatically: sleep
latency (SL), sleep efficiency (SE), percentage of N1, N2,
N3 of NREM sleep and rapid eye movement (REM)
sleep. The quality of sleep after awakening was assessed
by the subjective Sleep Quality Scale (SQS) and subject-
ive Sleep Depth Scale (SDS). The results of the SQS and
SDS are a quality score ranging from 1 (very poor) to 7
(very good). The Stanford Sleepiness Scale (SSS) was
used to assess the subjective sleepiness after awakening
[10]. The result of the SSS is a score with increasing
sleepiness from 1 to 7.
The psychomotor performance tests included a vigi-
lance and tracking dual task, choice reaction time (CRT)
and critical flicker fusion (CFF) frequency detections.
The vigilance and tracking dual task were performed on
a computer and measured the correct rate of four digit
addition and the correct rate of controlling the simu-
lated flying state of an airplane and the combination of
these tasks [11]. The CRT test was conducted to assess
the recognition reaction time when red, green or yellow
lights were randomly presented [12]. The individual CFF
frequency was determined using the mean of two
ascending and two descending presentations [12].
The computerized vestibular function examination
apparatus was used to evaluate the vestibular function.
This system was produced by Beijing Heping Medical In-
strument Factory and operated by the Institute of Aviation
Medicine. The vestibular function evaluation protocols
include optokinetic nystagmus (OKN), vestibular ocular
reflex (VOR), visual-vestibular ocular reflex (VVOR) and
vestibular ocular reflex fixation suppression (VOR-Fix)
[13]. During the process of the VOR and VOR-Fix tests,
nystagmus was induced by sinusoidal angular rotation in
horizontal plane at 0.05 Hz and a peak velocity of 60°/s.
While the VVOR test was performed, nystagmus was
induced by both sinusoidal angular rotation with a peak
velocity of 60°/s in the horizontal plane at 0.05 Hz and by
stripes on a wall. When the OKN test was conducted,
OKN was induced by full-field sinusoidal moving visual
stimuli at 0.05 Hz and a peak velocity of 60°/s. The gain in
the nystagmus response during stimulation for three
cycles was calculated by a computer.
Design and treatments
For measuring the sleep-inducing effects, using the
double-dummy technique, a single dose of 10 mg or 15 mg
of zaleplon (Sibao Pharmaceutical Company, Wuhan,
China) or placebo were randomly used in a double-blind
crossover design. Between the drug administrations, there
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was a wash-out period of 7 days. A randomized, double-
blind repeated-measures protocol was designed to assess
the effect of zaleplon at two doses and placebo on psycho-
motor performance. To maintain the double-blind nature
of this work, all medications were prepared in identical
capsule format.
Procedure
The volunteers were medically examined and instructed
to abstain from the use of hypnotics or psychoactive
drugs (tranquilizers) for 1 wk before any experimental
session, and from alcohol, over-the-counter medications
and caffeinated beverages within 12 h of each experi-
mental session. The volunteers were instructed to main-
tain regular sleep/wake cycles during the study and to
avoid strong sports. As they were exposed to the simu-
lated noise environment (150 Hz, approximately 95 dB),
eight volunteers took 10 mg or 15 mg of zaleplon and
placebo alternately at 14:00 pm. PSG for 4 h after taking
pills was recorded. After awakening, their subjective
judgments of sleep quality and sleepiness were assessed.
Eight volunteers were trained to participate in the
psychomotor performance tests. On the days of the tests,
each subject performed a baseline test session at 11:00 am.
The subjects were tested for psychomotor performance
once at 14:00 pm, 15:00 pm, 16:00 pm, 17:00 pm,
19:00 pm and 21:00 pm, for six times in total after taking
10 mg or 15 mg zaleplon and placebo alternately at
13:00 pm. Another six volunteers participated in the
vestibular function evaluation with the same experimental
design and procedure.
Data analysis
The sleep data were subjected to one-way analysis of
variances (ANOVA) using SPSS 13.0 statistical software.
The experimental data of psychomotor performance and
the vestibular function evaluations were subjected to
repeated-measures analysis of variance with two factors
(drug and time). P < 0.05 was used as the level of signifi-
cance for the ANOVAs and for post hoc testing of the
significant drug × trial interactions.
Results
Sleep process and sleep structure
The results are presented in Table 1. Significant differ-
ences in the SL, SE and REM% were observed among
the three groups (F(2, 21) = 24.05, 29.94 and 22.54, re-
spectively, P < 0.01). Compared with the placebo group,
the SL in the zaleplon 10 mg group was significantly
decreased (P < 0.05). In the zaleplon 15 mg group, the
SL was significantly decreased, and the SE and REM%
were remarkably increased (P < 0.01) compared with the
placebo group and the zaleplon 10 mg group. In the
zaleplon 15 mg group, the percentage of slow wave sleep
in N3 was significantly decreased (P < 0.01) compared
with the zaleplon 10 mg group.
Subjective evaluations of sleep quality and sleepiness
after awakening
As shown in Table 2, there were significant differences
in the scores of subjective SQS and SDS among the
three groups (F(2, 21) = 13.043 and 13.233, respectively,
P < 0.01). Compared with the placebo group, the score
of the subjective SQS was significantly enhanced in the
zaleplon 10 mg and zaleplon 15 mg groups after awak-
ening (P < 0.01). Compared with the placebo group, the
scores of the subjective SDS were also significantly en-
hanced in the zaleplon administered groups (P < 0.05).
Compared with the zaleplon 10 mg group, the subject-
ive SDS score was markedly increased after ingestion of
zaleplon 15 mg (P < 0.05). However, there were no obvi-
ous differences of subjective sleepiness among the three
groups after awakening.
Psychomotor performance
There were no significant differences for the correct rate
and maintaining the rate of the dual tasks (F(2, 21) =
0.047 and 0.372, P > 0.05, Table 3) among the three
groups. Compared with the placebo, the reaction times
of red, green and yellow lights (F(2, 21) = 0.113, 0.813 and
0.675, P > 0.05) were slightly prolonged after taking zale-
plon 10 mg and 15 mg; however, there were no
Table 1 Effects of zaleplon at two doses on sleep process and








Sleep latency (min) 27.50 ± 10.92 11.19 ± 2.05* 5.75 ± 2.12**
Sleep efficiency (%) 68.71 ± 6.04 69.63 ± 3.69 87.40 ± 6.22**ΔΔ
Sleep structure
N1 (%) 32.58 ± 5.68 29.52 ± 3.77 31.58 ± 5.26
N1 (%) 45.86 ± 8.98 42.37 ± 6.68 37.95 ± 10.16
N3 (%) 15.21 ± 7.01 20.96 ± 7.87 12.71 ± 3.97Δ
REM (%) 6.35 ± 3.44 7.16 ± 2.76 17.76 ± 4.87**ΔΔ
Maximum time in bed was 270 min. *P < 0.05, **P < 0.01 compared with
placebo group; △P < 0.05, ΔΔP < 0.01 compared with zaleplon 10 mg group
Table 2 Effects of zaleplon at two doses on subjective sleep







Scores of SQS 3.75 ± 1.04 5.38 ± 0.92** 6.00 ± 0.76**
Scores of SDS 3.25 ± 1.04 4.62 ± 1.41* 6.12 ± 0.83**Δ
Scores of SSS 2.38 ± 0.92 2.12 ± 0.64 2.38 ± 0.92
The subjective evaluations were carried out after awakening. *P < 0.05, **P < 0.01
compared with placebo; ΔP < 0.05 compared with zaleplon 10 mg group
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significant differences among the groups. Compared
with the placebo, the CFF was slightly decreased after
taking zaleplon 10 mg and 15 mg, although no sig-
nificant differences were observed among the three
groups (F(2, 21) = 0.327, P > 0.05).
Vestibular function
Compared with the placebo group, the OKN gain was
significantly decreased in the two dose groups of zale-
plon (F(2, 15) = 10.81, P < 0.05, Fig. 1) and restored to
normal 3 h after drug ingestion; the same trend was
observed for the VOR gain (F(2, 15) = 39.64, P < 0.05),
whereas the VVOR and VOR-Fix gains did not change
significantly at any times points after ingestion of zale-
plon 10 mg and 15 mg. Every time subjects in the three
groups gazed at the fixed light, vestibular nystagmus was
completely inhibited. The nystagmogram showed a
nearly single line, which indicates that fixation suppres-
sion was complete.
Other adverse effects observation
Compared with the placebo group and the zaleplon
10 mg group, zaleplon at a dose of 15 mg caused signifi-
cant drowsiness up to 2 h postdose during the psycho-
motor performance and vestibular test sessions. No
other adverse effects were observed or reported after
taking 10 mg or 15 mg of zaleplon.
Discussion
Zaleplon is commonly administered at 10 mg oral doses,
although some experiments showed that this dosage had
no significant sleep-inducing effects. Drake et al. [14]
found that zaleplon 10 mg produced a decrease in
latency to persistent sleep that was comparable with that
of triazolam 0.25 mg but did not produce significant in-
creases in total sleep time over placebo for patients with
chronic primary insomnia. Simons et al. [8] observed the
usefulness of temazepam (20 mg) and zaleplon (10 mg)
to improve 4.5 h of sleep in the afternoon and found
that the use of zaleplon had no significant advantage
Table 3 Effects of zaleplon at two doses on the correct rate of dual task (x  s, n = 8)
Group Baseline Time after taking drug
1 h 2 h 3 h 4 h 6 h 8 h
Placebo 92.99 ± 3.27 90.78 ± 7.15 91.86 ± 5.06 89.83 ± 6.88 90.55 ± 3.59 90.79 ± 4.34 90.86 ± 5.53
Zaleplon 10 mg 88.54 ± 8.58 88.59 ± 6.53 89.66 ± 4.33 90.09 ± 4.37 93.31 ± 4.92 92.34 ± 5.24 92.76 ± 5.55
Zaleplon 15 mg 87.01 ± 6.31 92.38 ± 3.34 88.82 ± 4.38 91.65 ± 6.82 91.37 ± 4.57 90.48 ± 4.21 91.76 ± 6.21
The baseline of the placebo group served as 100 %; F(2, 21) = 0.047, P > 0.05
Fig. 1 Effects of zaleplon on optokinetic nystagmus (OKN) gain. *P < 0.05 compared with placebo
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over placebo. The results of this study showed that
zaleplon 15 mg provided significantly superior sleep
compared with zaleplon 10 mg or the placebo under
noise interference.
The methods of evaluating the effects of drugs on cen-
tral functions mainly include cognitive performance,
CRT, CFF, some subjective psychological scales and
others [15, 16]. Paul et al. [17] compared the effect of a
single dose of zaleplon (10 mg), zopiclone (7.5 mg), tem-
azepam (15 mg), and melatonin (6 mg) on psychomotor
performance and quantified the post-ingestion time
required for return to normal performance. The results
showed that melatonin was superior to zaleplon in caus-
ing no effect on performance. The remaining drugs
listed in increasing order of performance effect duration
were zaleplon (2.25–3.25 h), temazepam (4.25–6.25 h),
and zopiclone (3.25–5.25 h). Whitmore et al. [18] re-
ported that zaleplon (10 mg), when used as a daytime
sleep aid, causes drowsiness (and related symptoms) up
to 3 h postdose and might affect task performance,
especially more complex tasks, for at least 2–3 h post-
dose. Verster et al. [19] observed the effects of a
middle-of-the-night administration of zaleplon 10 or
20 mg, zolpidem 10 or 20 mg, or placebo on driving
ability 4 h after administration and on memory and
psychomotor performance 6 h after administration. The
results showed that zaleplon (10 and 20 mg) was a safe
hypnotic devoid of next-morning residual impairment
when used in the middle of the night. However, a
higher number of adverse events were observed with
the 40 and 60 mg doses of zaleplon compared with tria-
zolam (0.25) and placebo [14]. Therefore, the present
results are in accordance with the results of previous
studies [17–19], although some differences exist due to
the variances of participants and experimental conditions.
Vestibular function is very important for spatial orien-
tation and anti-air sickness of aircrew and some other
special military personnel. In general, the vestibular op-
tokinetic reflex of human beings is easily regulated by
the cerebral cortex; OKN is mainly influenced by the
cerebral cortex and brain stem; VOR-Fix suppression is
influenced by the cerebellum; and the vestibular nuclei,
cerebellum and reticular structure in the brain stem play
important roles in the regulation of the visual-vestibular
optokinetic reflex. A variety of drugs, especially barbitu-
rates, antihistamines, anticonvulsants and alcohol, could
induce functional excitation or inhibition of the central
nervous system and influence vestibular function [13].
Collins [20] observed that under stimulation with angu-
lar acceleration, d-amphetamine significantly increased
nystagmus and enhanced the “rotation” experience of
subjects during 55 h of sleep deprivation. In our previ-
ous study, OKN gain in the modafinil group was
increased significantly during 24 h of sleep deprivation,
and the drug’s effect was maintained for 1–7 h, which
might be related to its central stimulation effects and
pharmacokinetic features [21, 22]. In this study, the
OKN and VOR gains were lower in the two zaleplon
dose groups (P < 0.05) and restored to normal 3 h after
drug ingestion. These results are in accordance with the
experimental observation of its effects on psychomotor
performance, which could be explained by its minor
central inhibitive effects and very short half-life [23]. In
addition, some related literature reported that zaleplon
did not influence performance under altitude environ-
ment and did not influence driving ability [24–26].
Based on the hypnotic efficiency and the adverse effects
on central function, zaleplon is an ideal hypnotic for
aircrew and some other military personnel.
Conclusion
Modern military operations might require pharmaco-
logical methods to sustain alertness and facilitate sleep to
maintain operational readiness. In operations with very
limited sleep windows, hypnotics with a very short half-
life might be used. Based on the hypnotic efficiency and
the adverse effects on central function, zaleplon is an ideal
hypnotic for aircrew and some other military personnel,
and the optimal single dosage for sleep induction could be
increased from the routine 10 mg to 15 mg.
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